News

The investment, which originated from Paul Manning, a director of the National Neurovision Research Institute (NNRI), is supporting the continuing development of StarGen. StarGen is Oxford BioMedica’s novel

The award funds continued development of PL 4500, a molecular complex of indomethacin and phosphatidylcholine that is being developed as a gastrointestinal (GI) safer anti-inflammatory and analgesic in

Under a collaboration agreement between the University of California, San Diego (UCSD) and Raptor, UCSD is conducting the Phase IIa clinical trial at UCSD’s General Clinical Research Center.

Further, AspenBio Pharma said it promoted Mark Colgin to a new position of chief scientific officer. “We are very grateful for Rich’s invaluable contribution over the last few

Revenues for the fourth quarter of 2008 were $10.1 million, up from $7.8 million in the fourth quarter of 2007. For the full year 2008, revenues were $35.2

Reported sales of $510 million in the fourth quarter ended December, 2008 declined by 4% compared to 2007. Excluding the impact of currency, sales in the fourth quarter

The new agreement addresses the five existing technologies and two applications in development of the Artelon spacer portfolio designed to treat arthritis within small bone and joints. Small

According to the company, the new connector system, which includes the Durata defibrillation lead with the SJ4 connector and the Promote CRT-D with the SJ4 connector, is expected

The open-label, dose-escalating pivotal trial has been designed to measure durable local complete response at the tumor site. Celsion expects to enroll approximately 100 patients across the US